The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled Trial
The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled Trial
复制标题
DOI：
10.1007/s12602-018-9490-z
复制
发表时间：
2019-12-01
影响因子：
4.9
通讯作者：
Asemi, Zatollah
中科院分区：
文献类型：
--
作者：
Babadi, Mahtab;Khorshidi, Ahmad;Asemi, Zatollah
本研究旨在评估益生菌补充对未口服降糖药的妊娠期糖尿病（GDM）患者遗传和代谢特征的影响。这项随机、双盲、安慰剂对照的临床试验在48例GDM患者中进行。参与者被随机分为两组，分别摄入含有嗜酸乳杆菌、干酪乳杆菌、两歧双歧杆菌、发酵乳杆菌的益生菌胶囊（各2x 10（9）CFU/g）（n=24）或安慰剂（n=24），持续6周。益生菌摄入上调GDM患者外周血单个核细胞过氧化物酶体增殖物激活受体γ（P=0.01）、转化生长因子β（P=0.002）和血管内皮生长因子（P=0.006），下调肿瘤坏死因子α（P=0.03）基因表达。此外，益生菌补充剂显著降低空腹血糖（β，-3.43 mg/dL; 95% CI，-6.48，-0.38; P=0.02），血清胰岛素水平（β，-2.29 mu IU/mL; 95% CI，-3.60，-0.99; P=0.001）和胰岛素抵抗（β，-0.67; 95% CI，-1.05，-0.29; P=0.001）和胰岛素敏感性显著增加（β，0.009; 95% CI，0.004，0.01; P=0.001）。此外，与安慰剂相比，食用益生菌显著降低甘油三酯（P= 0.02），VLDL-胆固醇（P=0.02）和总/HDL-胆固醇比率（P=0.006），并显著增加HDL-胆固醇水平（P=0.03）。最后，益生菌给药导致血浆丙二醛显著降低（P
This study was carried out to evaluate the effects of probiotic supplementation on genetic and metabolic profiles in patients with gestational diabetes mellitus (GDM) who were not on oral hypoglycemic agents. This randomized, double-blind, placebo-controlled clinical trial was conducted in 48 patients with GDM. Participants were randomly divided into two groups to intake either probiotic capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum (2x10(9) CFU/g each) (n=24) or placebo (n=24) for 6 weeks. Probiotic intake upregulated peroxisome proliferator-activated receptor gamma (P=0.01), transforming growth factor beta (P=0.002) and vascular endothelial growth factor (P=0.006), and downregulated gene expression of tumor necrosis factor alpha (P=0.03) in peripheral blood mononuclear cells of subjects with GDM. In addition, probiotic supplementation significantly decreased fasting plasma glucose (beta, -3.43 mg/dL; 95% CI, -6.48, -0.38; P=0.02), serum insulin levels (beta, -2.29 mu IU/mL; 95% CI, -3.60, -0.99; P=0.001), and insulin resistance (beta, -0.67; 95% CI, -1.05, -0.29; P=0.001) and significantly increased insulin sensitivity (beta, 0.009; 95% CI, 0.004, 0.01; P=0.001) compared with the placebo. Additionally, consuming probiotic significantly decreased triglycerides (P=0.02), VLDL-cholesterol (P=0.02), and total-/HDL-cholesterol ratio (P=0.006) and significantly increased HDL-cholesterol levels (P=0.03) compared with the placebo. Finally, probiotic administration led to a significant reduction in plasma malondialdehyde (P